EnBio Holdings, Inc Fundamental Analysis (JPX: 6092.T)
EnBio Holdings, Inc (JPX: 6092.T) shows weak financial fundamentals with a PE ratio of 21.80, profit margin of 2.10%, and ROE of 2.89%. The company generates $12.6B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 28.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 6092.T's fundamental strength across five key dimensions:
Efficiency Score
Weak6092.T struggles to generate sufficient returns from assets.
Valuation Score
Excellent6092.T trades at attractive valuation levels.
Growth Score
Moderate6092.T shows steady but slowing expansion.
Financial Health Score
Moderate6092.T shows balanced financial health with some risks.
Profitability Score
Weak6092.T struggles to sustain strong margins.
Key Financial Metrics
Is 6092.T Expensive or Cheap?
P/E Ratio
6092.T trades at 21.80 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, 6092.T's PEG of -0.09 indicates potential undervaluation.
Price to Book
The market values EnBio Holdings, Inc at 0.62 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -0.38 times EBITDA. This is generally considered low.
How Well Does 6092.T Make Money?
Net Profit Margin
For every $100 in sales, EnBio Holdings, Inc keeps $2.10 as profit after all expenses.
Operating Margin
Core operations generate 12.82 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $2.89 in profit for every $100 of shareholder equity.
ROA
EnBio Holdings, Inc generates $1.16 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
EnBio Holdings, Inc generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
EnBio Holdings, Inc generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
6092.T converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
21.80
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.09
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.62
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.46
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.15
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.20
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.03
vs 25 benchmark
ROA
Return on assets percentage
0.01
vs 25 benchmark
ROCE
Return on capital employed
0.09
vs 25 benchmark
How 6092.T Stacks Against Its Sector Peers
| Metric | 6092.T Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 21.80 | 30.52 | Better (Cheaper) |
| ROE | 2.89% | 1172.00% | Weak |
| Net Margin | 2.10% | -20786.00% (disorted) | Weak |
| Debt/Equity | 1.15 | 0.38 | Weak (High Leverage) |
| Current Ratio | 2.20 | 24.22 | Strong Liquidity |
| ROA | 1.16% | -1311221.00% (disorted) | Weak |
6092.T outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews EnBio Holdings, Inc's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Cyclical, Value, Infrastructure
EPS CAGR
N/A
Industry Style: Cyclical, Value, Infrastructure
FCF CAGR
N/A
Industry Style: Cyclical, Value, Infrastructure